Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
Innate Pharma to present MATISSE Phase 2 interim results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
Innate Pharma reports full year 2025 financial results and business update
Innate Pharma reports Third Quarter 2025 business update and financial results
Innate Pharma announces FDA clearance to proceed with TELLOMAK 3, a confirmatory Phase 3 trial of lacutamab in CTCL
Innate Pharma to host analyst and investor event on lacutamab on October 28, 2025
Innate Pharma Reports First Half 2025 Business Update And Financial Results
Innate Pharma highlights preclinical antitumor activity of IPH6501 in diffuse large B-cell lymphoma and follicular lymphoma at the 2025 European Hematology Association (EHA) congress
Innate Pharma highlights durable responses to lacutamab in Sezary syndrome and mycosis fungoides
Innate Pharma highlights abstracts selected for ASCO 2025 annual meeting
